Oxygen radical formation does not have an impact in the treatment of severe acute experimental pancreatitis using free cellular hemoglobin.
OBJECTIVE
Microcirculatory dysfunction and free oxygen radicals are important factors in the pathogenesis of severe acute pancreatitis. Additional oxygen delivery might enhance lipid peroxidation but may also improve pancreatic microcirculation. This study assesses the effect of free cellular bovine hemoglobin on the formation of oxygen radicals and microcirculation in a rodent model of severe acute pancreatitis.


METHODS
Fifteen minutes after induction of acute pancreatitis Wistar rats received either 0.8 mL bovine hemoglobin (HBOC-200), hydroxyethyl starch (HES) or 2.4 mL of normal saline to ensure normovolemic substitution. After 6 h of examination the pancreas was excised and rapidly processed for indirect measurement of lipid peroxidation products malondialdehyde (MDA) and reduced glutathione (GSH) in pancreatic tissue.


RESULTS
The single application of HBOC-200 improved pancreatic microcirculation and reduced histopathological tissue damage significantly. Tissue concentration of MDA did not differ between the groups. Also no differences in GSH levels were detected.


CONCLUSIONS
Though the single application of HBOC-200 and HES improve pancreatic microcirculation, no differences in lipid peroxidation products were detected. The beneficial effect of additional oxygen supply (HBOC-200) does not lead to enhanced lipid peroxidation.
Kleinhans
Helge
H
Department of General-, Visceral- and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Mann
Oliver
O
Schurr
Paulus G
PG
Kaifi
Jussuf T
JT
Hansen
Bente
B
Izbicki
Jakob R
JR
Strate
Tim
T
D000208:Acute Disease; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006454:Hemoglobins / Q000494:pharmacology / Q000627:therapeutic use*; D006895:Hydroxyethyl Starch Derivatives / Q000494:pharmacology / Q000627:therapeutic use; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology; D008833:Microcirculation / Q000502:physiology; D010179:Pancreas / Q000098:blood supply / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D010195:Pancreatitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D010952:Plasma Substitutes / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D012039:Regional Blood Flow / Q000502:physiology
D006454:Hemoglobins; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D017382:Reactive Oxygen Species; C402601:hemoglobin glutamer-200